Post-hoc analyses suggested that the reductions in PSA progression and decreased need for secondary therapeutic intervention with ITAS plus zoledronic acid were restricted to tumours with a Gleason score of @-@ , and that ITAS was better than STAS in tumours with a Gleason score of @ or lower .